BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tang S, Huang W, Lu S, Lu L, Li G, Chen X, Liu X, Lv X, Zhao Z, Duan R, Du Y, Tang J. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides 2017;88:55-61. [PMID: 27988352 DOI: 10.1016/j.peptides.2016.12.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Campbell EJ, Norman A, Bonomo Y, Lawrence AJ. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial. Brain Res 2020;1728:146597. [PMID: 31837287 DOI: 10.1016/j.brainres.2019.146597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Mäkelä KA, Karhu T, Jurado Acosta A, Vakkuri O, Leppäluoto J, Herzig KH. Plasma Orexin-A Levels Do Not Undergo Circadian Rhythm in Young Healthy Male Subjects. Front Endocrinol (Lausanne) 2018;9:710. [PMID: 30568633 DOI: 10.3389/fendo.2018.00710] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
3 Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, Bai B, Chen J. The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Front Mol Neurosci 2018;11:220. [PMID: 30002617 DOI: 10.3389/fnmol.2018.00220] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
4 Zhang B, Guo D, Han L, Rensing N, Satoh A, Wong M. Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2020;134:104615. [PMID: 31605778 DOI: 10.1016/j.nbd.2019.104615] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
5 Huang S, Zhao Z, Ma J, Hu S, Li L, Wang Z, Sun W, Shi X, Li M, Zheng J. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients. Neurosci Lett 2021;741:135480. [PMID: 33161104 DOI: 10.1016/j.neulet.2020.135480] [Reference Citation Analysis]
6 Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults. Clin Pharmacol Drug Dev 2021;10:153-65. [PMID: 32468649 DOI: 10.1002/cpdd.817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
7 Dong YJ, Jiang NH, Zhan LH, Teng X, Fang X, Lin MQ, Xie ZY, Luo R, Li LZ, Li B, Zhang BB, Lv GY, Chen SH. Soporific effect of modified Suanzaoren Decoction on mice models of insomnia by regulating Orexin-A and HPA axis homeostasis. Biomed Pharmacother 2021;143:112141. [PMID: 34509822 DOI: 10.1016/j.biopha.2021.112141] [Reference Citation Analysis]
8 Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 2021;238:2693-708. [PMID: 34415378 DOI: 10.1007/s00213-021-05954-0] [Reference Citation Analysis]
9 Gottschalk MG, Richter J, Ziegler C, Schiele MA, Mann J, Geiger MJ, Schartner C, Homola GA, Alpers GW, Büchel C, Fehm L, Fydrich T, Gerlach AL, Gloster AT, Helbig-Lang S, Kalisch R, Kircher T, Lang T, Lonsdorf TB, Pané-Farré CA, Ströhle A, Weber H, Zwanzger P, Arolt V, Romanos M, Wittchen HU, Hamm A, Pauli P, Reif A, Deckert J, Neufang S, Höfler M, Domschke K. Orexin in the anxiety spectrum: association of a HCRTR1 polymorphism with panic disorder/agoraphobia, CBT treatment response and fear-related intermediate phenotypes. Transl Psychiatry 2019;9:75. [PMID: 30718541 DOI: 10.1038/s41398-019-0415-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
10 Wang Q, Wang X, Yang C, Wang L. The role of sleep disorders in cardiovascular diseases: Culprit or accomplice? Life Sci 2021;283:119851. [PMID: 34324916 DOI: 10.1016/j.lfs.2021.119851] [Reference Citation Analysis]
11 Kaplan GB, Lakis GA, Zhoba H. Sleep-Wake and Arousal Dysfunctions in Post-Traumatic Stress Disorder:Role of Orexin Systems. Brain Res Bull 2022:S0361-9230(22)00121-6. [PMID: 35618150 DOI: 10.1016/j.brainresbull.2022.05.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nakashima H, Umegaki H, Yanagawa M, Komiya H, Watanabe K, Kuzuya M. Plasma orexin-A-like immunoreactivity levels and renal function in patients in a geriatric ward. Peptides 2019;118:170092. [DOI: 10.1016/j.peptides.2019.170092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Palagini L, Bastien CH, Marazziti D, Ellis JG, Riemann D. The key role of insomnia and sleep loss in the dysregulation of multiple systems involved in mood disorders: A proposed model. J Sleep Res 2019;28. [DOI: 10.1111/jsr.12841] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
14 Waters K. Review of the Efficacy and Safety of Lemborexant, a Dual Receptor Orexin Antagonist (DORA), in the Treatment of Adults With Insomnia Disorder. Ann Pharmacother 2021;:10600280211008492. [PMID: 34078141 DOI: 10.1177/10600280211008492] [Reference Citation Analysis]
15 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
16 Hu S, Niu J, Zhang R, Li X, Luo M, Sang T, Guo J, Liu J, Ding X, Li X, Ma Y, Gao R. Orexin A associates with inflammation by interacting with OX1R/OX2R receptor and activating prepro-Orexin in cancer tissues of gastric cancer patients. Gastroenterol Hepatol 2020;43:240-7. [PMID: 31983458 DOI: 10.1016/j.gastrohep.2019.10.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Cao Y, Zhang L, Peng X, Wu Y, Zhang Q, Gu E, Zhang Y. Increased minimum alveolar concentration-awake of Sevoflurane in women of breast surgery with sleep disorders. BMC Anesthesiol 2020;20:17. [PMID: 31959101 DOI: 10.1186/s12871-020-0931-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jin K, Lu J, Yu Z, Shen Z, Li H, Mou T, Xu Y, Huang M. Linking peripheral IL-6, IL-1β and hypocretin-1 with cognitive impairment from major depression. J Affect Disord 2020;277:204-11. [PMID: 32829196 DOI: 10.1016/j.jad.2020.08.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Soysal P, Smith L, Dokuzlar O, Isik AT. Relationship Between Nutritional Status and Insomnia Severity in Older Adults. Journal of the American Medical Directors Association 2019;20:1593-8. [DOI: 10.1016/j.jamda.2019.03.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
20 Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Curr Hypertens Rep. 2018;20:79. [PMID: 29992504 DOI: 10.1007/s11906-018-0879-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
21 Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, Perdomo C, Landry I, Majid O, Van Oers ACM, Van Leeuwen CJ, Ramaekers JG, Vuurman EFPM. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep 2019;42:zsy260. [PMID: 30597112 DOI: 10.1093/sleep/zsy260] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]